Disclosed are compounds, for example, compounds of formula I,

##STR00001##

wherein R, R.sub.0, R.sub.1-R.sub.8, n, X, Y, Y, and E are as described herein, pharmaceutical compositions containing such compounds, and methods of treating or preventing a disease or condition, for example, cancer.

Disclosed are compounds, for example, compounds of formula I,

##STR00001##

wherein R, R.sub.0, R.sub.1-R.sub.8, n, X, Y, Y, and E are as described herein, pharmaceutical compositions containing such compounds, and methods of treating or preventing a disease or condition, for example, cancer.

Disclosed are compounds, for example, compounds of formula I,

##STR00001##

wherein R, R.sub.0, R.sub.1-R.sub.8, n, X, Y, Y, and E are as described herein, pharmaceutical compositions containing such compounds, and methods of treating or preventing a disease or condition, for example, cancer.

Disclosed are compounds, for example, compounds of formula I,

##STR00001##

wherein R, R.sub.0, R.sub.1-R.sub.8, n, X, Y, Y, and E are as described herein, pharmaceutical compositions containing such compounds, and methods of treating or preventing a disease or condition, for example, cancer.

The present invention relates to novel 5-hydroxy pyridine-based compounds useful as P2X1 and P2X3 receptor antagonists and compositions comprising the same. The compounds according to the present invention have an activity of strongly antagonizing P2X1 and P2X3 receptors, and thus can be effectively used as a drug for treating or preventing chronic inflammatory diseases or neuropathic pain diseases caused by P2X1 and P2X3 receptor activity.

The present invention provides a palladium(II) complex of formula (1) or a palladium(II) complex of formula (2).

##STR00001##

R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7, R.sub.8, R.sub.9, R.sub.10, R.sub.11, R.sub.12, R.sub.18, R.sub.19, R.sub.20, R.sub.21, R.sub.22, R.sub.23 and R.sub.24, m, E and X are described in the specification. The invention also provides a process for the preparation of the complexes, and their use in carbon-carbon and carbon-heteroatom coupling reactions.

The present invention provides a palladium(II) complex of formula (1) or a palladium(II) complex of formula (2).

##STR00001##

R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7, R.sub.8, R.sub.9, R.sub.10, R.sub.11, R.sub.12, R.sub.18, R.sub.19, R.sub.20, R.sub.21, R.sub.22, R.sub.23 and R.sub.24, m, E and X are described in the specification. The invention also provides a process for the preparation of the complexes, and their use in carbon-carbon and carbon-heteroatom coupling reactions.

Compounds of Formula 1 as inhibitors of protein tyrosine phosphatase SHP2 are disclosed. The pharmaceutical compositions comprising compounds of Formula 1, methods of synthesis of these compounds, methods of treatment for diseases associated with the aberrant activity of SHP2 such as cancer using these compounds or compositions containing these compounds are also disclosed.

Disclosed are compounds, for example, compounds of formula I,

##STR00001##

wherein R, R.sub.0, R.sub.1-R.sub.8, n, X, Y, Y, and E are as described herein, pharmaceutical compositions containing such compounds, and methods of treating or preventing a disease or condition, for example, cancer.

Disclosed are compounds, for example, compounds of formula I,

##STR00001##

wherein R, R.sub.0, R.sub.1-R.sub.8, n, X, Y, Y, and E are as described herein, pharmaceutical compositions containing such compounds, and methods of treating or preventing a disease or condition, for example, cancer.